Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Prostascint

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
INTRODUCTION In this study, a structurally modified phosphoramidate scaffold, with improved prostate-specific membrane antigen… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2014
Highly Cited
2014
PURPOSE We prospectively evaluated the amino acid analogue positron emission tomography radiotracer anti-3-[(18)F]FACBC compared… Expand
Review
2013
Review
2013
PURPOSE Molecular imaging methods may identify primary prostate cancer foci and potentially guide biopsy and optimal management… Expand
  • figure 1
  • table 1
  • table 2
  • figure 3
  • table 3
2008
2008
PURPOSE We evaluate the usefulness of pretreatment (111)Indium capromab pendetide (ProstaScint) planar imaging… Expand
Review
2005
Review
2005
Purpose of review Despite marked stage migration, approximately a third of patients with clinically organ-confined prostate… Expand
Review
2001
Review
2001
PURPOSE Capromab pendetide (ProstaScint) is an indium In 111 ((111)In)-labeled monoclonal antibody to prostate-specific membrane… Expand
2001
2001
I agreed to enter a debate siding against the value of indium-111 (In)-capromab pendetide (Cyt-356) (ProstaScint) imaging with… Expand
2000
2000
We report on the demonstration of nonspecific accumulation of indium-111 capromab pendetide (ProstaScint) in neurofibromas in a… Expand